Myomancy ADHD, Dyslexia and Autism

May 2008

VYVANSE Demonstrated Significant Improvement In ADHD Symptoms In … - Medical News Today (press release)

APA: Just-Approved Adult ADHD Drug Shows Symptom Improvement - MedPage Today

Hyperactivity drug goes too slow for Shire - guardian.co.uk

VYVANSE Demonstrated Significant Improvement in ADHD Symptoms in … - HealthNewsDigest.com

Albany Molecular Research Inc. Q1 2008 Earnings Call Transcript - Seeking Alpha

Shire sales beat consensus; 2008 guidance confirmed, sees growth … - Forbes

Shire Q1 Profit Up 14%; Reiterates FY08 Revenue Outlook; Sees … - RTT News

Shire sees upside to Vyvanse sales forecast - Therapeutics Daily (subscription) (press release)

Shire ADHD Treatment Approved for Adults - FDA news (subscription)

April 2008

Barratt Developments hit hard by writedown worries - Times Online

ROUNDUP Shire Q1 in line, share volatility caused by Vyvanse … - Forbes

Shire: FDA approves Vyvanse for treatment of ADHD in adults - Forbes

ADRs in Focus: Shire rises on expanded Vyvanse approval - Forbes

Think ADHD is Just for Kids? Think Again - HealthNewsDigest.com

Shire Receives FDA Approval For Vyvanse To Treat Attention Deficit … - RTT News

Vyvanse approved for adult ADHD - Prescribing Reference

Shire Gets FDA approval of Vyvanse for adult use - Basingstoke Business News (press release)

Shire Wins US FDA Approval of Vyvanse Use in Adults (Update1) - Bloomberg

AstraZeneca sales disappoint, ups guidance - ShareCast

Shire Enhances its Orphan Drug Pipeline With the Acquisition of a … - PR Newswire (press release)

A&L shares rise despite rights issue pressure - guardian.co.uk

Shire Falls on Full-Year Forecast for Vyvanse Sales (Update2) - Bloomberg

Following a Good Start to the Year Shire Reaffirms Full Year 2008 … - PR Newswire (press release)

WPP and Shire lose ground - guardian.co.uk

FDA Okays Lisdexamfetamine Dimesylate (Vyvanse) for Adults with ADHD - MedPage Today

Following a Good Start to the Year Shire Reaffirms Full Year 2008 … - Biloxi Sun Herald

Shire Profit Up 14%, Sees Low-end Vyvanse Sales - FOXBusiness

FDA Approves Once-Daily Lisdexamfetamine to Treat ADHD in Adults - DG News

FDA Approves VYVANSE(TM) (lisdexamfetamine dimesylate), the First … - FOXBusiness

Shire Shares Decline on Full-Year Forecast for Vyvanse Sales - Bloomberg

FTSE positive thanks to US results - The Press Association

Dana Petroleum shares sing on North Sea oil find - Times Online

FTSE higher on drugs and commodities - Guardian

ADHD drug breakthrough boosts Shire - Guardian

Banks suffer after RBS rights issue - Telegraph.co.uk

New adult ADHD drug receives FDA approval - United Press International

FDA Approves VYVANSE(TM) (lisdexamfetamine dimesylate), the First … - FOXBusiness

ALSO NOTED: Bayer sues Watson over Yasmin; Zimmer weeds out doc … - FiercePharma

Heart Group Calls for Cardiac Tests for Kids Before ADHD Drugs - Wall Street Journal Blogs

DUE DILIGENCE: Shire As Bid Target: Could It Say No To AstraZeneca … - CNNMoney.com

New Shire Holding Company Proposal - Earthtimes

Zacks Bull and Bear of the Day - Ad-Hoc-News (Pressemitteilung)

Shire climbs on talk of Pfizer bid interest - International Herald Tribune

Options Update: Shire Pharmaceuticals (SHPGY) & Amazon.com (AMZN) - The Options Insider

Zacks Bull and Bear of the Day Highlights: Research in Motion … - Centre Daily Times

Movers Roundup: Auxilium, China Unicom - CNNMoney.com

Movers Roundup: Auxilium, China Unicom - Houston Chronicle

Heavyweights Fall Hard - Medical Marketing and Media

March 2008

Shire and TAP to co-promote ulcerative colitis drug Lialda - Pharma Times (subscription)

Jefferies Expects Continued Shire Growth - Houston Chronicle